Chatbot coaches cancer survivors on genetic testing
NCT ID NCT06184867
First seen Dec 11, 2025 · Last updated Jun 12, 2026 · Updated 23 times
Summary
This study tested a digital chatbot (called CATALYST) to help cancer survivors learn about genetic testing for inherited cancer risk. Fifty adults who had certain cancers (like breast, ovarian, or prostate) used the chatbot or received usual care. The goal was to see if the chatbot made genetic testing easier to understand and use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Rutgers University
New Brunswick, New Jersey, 08901, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.